Predictive Value of Positive Drug Screening Results in an Urban Outpatient Population.

Urine drug testing (UDT) has become an essential component in the management of patients prescribed opioid analgesics for the treatment of chronic non-malignant pain. Several laboratory methods are available to monitor adherence with the pharmacological regimen and abstinence from illicit or unauthorized medications. Immunochemical screening methods are rapid and economical, but they have limitations, including lack of specificity, and confirmatory methods are often necessary to verify presumptive positive results. We analyzed the results of confirmatory assays in an outpatient setting to determine the predictive value of presumptive positive urine drug screen results using an automated immunoassay for eight common drugs or drug classes. Positive predictive values (PPVs), in descending order, were as follows: cannabinoids (100%), cocaine (100%), opiates (86.8%), benzodiazepines (74.6%), oxycodone (67.6%), methadone (44.1%) and amphetamines (9.3%). The number of positive barbiturate results was too small to be included in the statistical analysis.

[1]  J. Genzen,et al.  A Retrospective Analysis of Urine Drugs of Abuse Immunoassay True Positive Rates at a National Reference Laboratory. , 2016, Journal of analytical toxicology.

[2]  M. Huestis,et al.  One Hundred False-Positive Amphetamine Specimens Characterized by Liquid Chromatography Time-of-Flight Mass Spectrometry. , 2015, Journal of Analytical Toxicology.

[3]  E. Cone,et al.  Metabolism and Disposition of Prescription Opioids: A Review. , 2015, Forensic science review.

[4]  Frederick G. Strathmann,et al.  A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays. , 2015, American journal of clinical pathology.

[5]  T. Robert,et al.  Immunoassay in healthcare testing applications. , 2015, Journal of opioid management.

[6]  G. Reisfield,et al.  Sensitivity of an opiate immunoassay for detecting hydrocodone and hydromorphone in urine from a clinical population: analysis of subthreshold results. , 2015, Journal of analytical toxicology.

[7]  Z. Chik,et al.  Quantitation of methadone and metabolite in patients under maintenance treatment. , 2014, Journal of analytical toxicology.

[8]  Robert L Fitzgerald,et al.  False-positive interferences of common urine drug screen immunoassays: a review. , 2014, Journal of analytical toxicology.

[9]  G. McMillin,et al.  Demystifying Analytical Approaches for Urine Drug Testing to Evaluate Medication Adherence in Chronic Pain Management , 2013, Journal of pain & palliative care pharmacotherapy.

[10]  M. Tanasijevic,et al.  Significant cost savings achieved by in-sourcing urine drug testing for monitoring medication compliance in pain management. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[11]  A. Pesce,et al.  Observations on the metabolism of morphine to hydromorphone in pain patients. , 2012, Journal of analytical toxicology.

[12]  Hans Hansen,et al.  American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. , 2012, Pain physician.

[13]  L. Manchikanti,et al.  Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing. , 2011, Pain physician.

[14]  L. Manchikanti,et al.  Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients. , 2011, Pain physician.

[15]  A. Fallgatter,et al.  False-positive methadone drug screens during quetiapine treatment. , 2010, Journal of Clinical Psychiatry.

[16]  G. Reisfield,et al.  Unexpected urine drug testing results in a hospice patient on high-dose morphine therapy. , 2009, Clinical chemistry.

[17]  G. Reisfield,et al.  Rational use and interpretation of urine drug testing in chronic opioid therapy. , 2007, Annals of clinical and laboratory science.

[18]  A. Hofer,et al.  Quetiapine cross reactivity with urine methadone immunoassays. , 2007, The American journal of psychiatry.

[19]  W. Clarke Contemporary Practice in Clinical Chemistry , 2006 .